The Law of Holes: Some Independents Skip 2019 Part D Preferred Pharmacy Networks

Last week, I highlighted the largest pharmacy chains that will participate in next year’s Medicare Part D prescription drug plans (PDP). Today, I examine independent pharmacies’ participation via the pharmacy services administrative organizations (PSAOs) that represent these pharmacies in negotiations with plans. This year’s results show a major divergence in strategies. Three of the four biggest PSAOs will participate in a comparable number of Part D networks, as the big chains do. AmerisourceBergen’s Elevate network, however, continues to go its own way and will skip preferred status in the major Part D networks. You will find its reasoning below. Are … Continue reading The Law of Holes: Some Independents Skip 2019 Part D Preferred Pharmacy Networks

McKesson: Biopharma Companies Need an Integrated, Customized and High-Touch Approach to Solve Critical Commercialization Challenges

Today’s guest post comes from Shawn Seamans, President of McKesson Life Sciences. Shawn discusses the channel and commercialization complexities associated with launching and managing specialty medications. He then outlines McKesson Life Sciences, a business that brings together McKesson’s multiple solutions for connecting biopharma companies, providers, pharmacies and payers. These solutions also help patients access their therapies. To learn more, visit McKesson Life Sciences or email LifeSciences@mckesson.com. Read on for Shawn’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use … Continue reading McKesson: Biopharma Companies Need an Integrated, Customized and High-Touch Approach to Solve Critical Commercialization Challenges

Battle Royale: CVS and Kroger Gain, Walgreens Slips in 2019 Part D Preferred Pharmacy Networks

In Humana Triggers a Pullback for Preferred Pharmacy Networks in 2019 Medicare Part D , I highlighted how preferred pharmacy networks will dominate next year’s Medicare Part D prescription drug plans (PDP). Today, I examine chain pharmacies’ participation in 24 major 2019 Part D preferred networks. Some highlights: CVS, for the second year, has strengthened its position as a preferred pharmacy in many 2019 networks. Walmart and Kroger have maintained the strong positions that they have established over the past few years. Walgreens, however, has slipped as the other chains grow. Poor ol’ Rite Aid will again be a preferred … Continue reading Battle Royale: CVS and Kroger Gain, Walgreens Slips in 2019 Part D Preferred Pharmacy Networks

EXCLUSIVE: Humana Triggers a Small Pullback for Preferred Pharmacy Networks in 2019 Medicare Part D (Plus: Top Sponsors and CVS Health’s POS Plan)

The Centers for Medicare & Medicaid Services (CMS) has recently released the initial raw data on the 2019 Medicare Part D plans. Our exclusive analysis of these data reveals that preferred cost sharing pharmacy networks will be slightly less popular next year. For 2019, 92% of Medicare Part D regional prescription drug plans (PDP) will have a preferred network. This figure compares with 99% of plans in 2018. The decline will occur primarily because two Humana plans will switch from preferred to open networks for 2019. Below, I provide historical context on preferred networks’ growth and then discuss the top … Continue reading EXCLUSIVE: Humana Triggers a Small Pullback for Preferred Pharmacy Networks in 2019 Medicare Part D (Plus: Top Sponsors and CVS Health’s POS Plan)

Join me at CBI’s 14th Life Sciences Trade and Channel Strategies

CBI’s 14th Life Sciences Trade and Channel Strategies December 11-12, 2018 | Philadelphia, PA www.cbinet.com/trade Are you ready for some channel strategy? Then join me at CBI’s 14th Life Sciences Trade and Channel Strategies Conference, being held this December in Philadelphia. CBI’s annual event has become our industry’s premier event focused on bio/pharma trade management. I’ll kick things off with an interactive keynote address titled Drug Channels Update – Things to Watch in 2019. I’ll highlight the key trends for the year ahead. I’ll also be moderating a panel with Wall Street experts. We’ll delve further into industry trends and … Continue reading Join me at CBI’s 14th Life Sciences Trade and Channel Strategies

DIR Fees: A Prescription While You Wait

Today’s guest post is sponsored by Elsevier and written by Todd Grover, Co-Founder, Glass Box Analytics and President, PharmacyFocus. Todd discusses some of the challenges associated with Direct and Indirect Remuneration (DIR) fees. He explains how Elsevier’s Predictive Acquisition Cost (PAC) pricing tool helps pharmacies better manage DIR fees and challenge insufficient reimbursements. Learn more by downloading Elsevier’s infographic: Managing the Impact of DIR Fees. Read on for Todd’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use only. … Continue reading DIR Fees: A Prescription While You Wait